Hyperimmune goat serum (Aimspro): hope or hype?
Sutton
Ian
I
St Vincent's Hospital, The Garvan Institute of Medical Research and Multiple Sclerosis Australia, Sydney, New South Wales Australia.
Kermode
Allan G
AG
D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000627:therapeutic use*; D020274:Autoimmune Diseases of the Nervous System / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D002986:Clinical Trials as Topic / Q000592:standards; D006041:Goats / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D044967:Serum / Q000276:immunology*
D000906:Antibodies; D000949:Histocompatibility Antigens Class II